Oral vs Injectable GLP-1: Orforglipron & Rybelsus vs Semaglutide & Tirzepatide
Summary
Injectable GLP-1s (Semaglutide 2.4mg → 15-17% weight loss, Tirzepatide → 20-22%) outperform orals (Rybelsus → 4-5%, Orforglipron 36mg → 7-10%) in raw efficacy. However, oral agents offer convenience and improved adherence. Orforglipron (Eli Lilly) outperformed oral semaglutide in a head-to-head Phase 3 trial (Lancet, Feb 2026). Injectables remain the gold standard for significant weight loss, while orals are ideal for mild obesity or as an introduction to therapy.
Substance Properties
What are GLP-1 agonists?
GLP-1 receptor agonists mimic endogenous GLP-1 hormone secreted by intestinal L-cells after meals. They act through: (1) delayed gastric emptying, (2) appetite reduction via central hypothalamic action, (3) glucose-dependent insulin secretion enhancement, and (4) glucagon suppression. The class includes both injectables (Semaglutide/Wegovy, Tirzepatide/Mounjaro) and oral formulations (Rybelsus, Orforglipron).
Injectable GLP-1: Semaglutide (Wegovy/Ozempic)
Semaglutide (Novo Nordisk) is a modified GLP-1 analogue with ~7-day half-life via albumin binding. STEP trials data: STEP 1 (n=1,961): -14.9% body weight at 68 weeks (2.4mg/wk). STEP 2 (T2D): -9.6%. STEP 5 (104 wk): -15.2% sustained. SELECT trial showed -20% cardiovascular events. Advantages: once-weekly injection, excellent efficacy. Disadvantages: injection required, GI side effects (nausea 44%, vomiting 24%).
Injectable GLP-1/GIP: Tirzepatide (Mounjaro/Zepbound)
Tirzepatide (Eli Lilly) is the first dual GLP-1/GIP agonist. SURMOUNT-1 (n=2,539): -22.5% body weight (15mg, 72 wk) — the highest in any obesity pharmacotherapy trial. 36.2% of participants achieved ≥25% weight loss. Currently considered the most effective pharmacological treatment for obesity.
Oral GLP-1: Rybelsus (Oral Semaglutide)
Rybelsus (Novo Nordisk) is the first approved oral GLP-1. Uses SNAC absorption enhancer for gastric absorption. PIONEER 1 (14mg): -4.7 kg (26 wk). Must be taken fasting, with ≤120mL water, 30 minutes before food. Bioavailability only ~1%.
Oral GLP-1: Orforglipron (Eli Lilly) — The Future?
Orforglipron (LY3502970) is a non-peptide, small molecule oral GLP-1 agonist — no SNAC needed. Phase 3 (NEJM, 2025): 6mg, 12mg, 36mg doses — -7.7% to -9.4% weight loss (36 wk). Head-to-head vs oral semaglutide (Lancet, Feb 2026): Orforglipron 36mg achieved statistically superior HbA1c and weight reduction at 52 weeks.
Efficacy Comparison: Oral vs Injectable
Tirzepatide injectable 15mg: -22.5% (72 wk). Semaglutide injectable 2.4mg: -14.9% (68 wk). Orforglipron oral 36mg: -9.4% (36 wk). Rybelsus oral 14mg: -4.7 kg (26 wk). Injectables outperform orals by 2-3x in raw efficacy. Tirzepatide remains the undisputed leader.
Safety Profile & Side Effects
GI side effects are common across all GLP-1 agents. Semaglutide injectable: nausea 44%, vomiting 24%. Tirzepatide: nausea 24-33% (better GI profile). Orforglipron: nausea 30-40%. Rybelsus: nausea 16-20% (lowest). Serious concerns: thyroid C-cell tumors (rodents), acute pancreatitis (rare), cholelithiasis. SELECT trial showed -20% MACE — significant cardiovascular benefit.
Relationship to research injectable peptides
Research injectable peptides (Semaglutide, Tirzepatide, Retatrutide) available as lyophilized powder are biochemically identical to approved drugs but are not subject to GMP quality control. Orforglipron, as a small molecule (not a peptide), cannot be reconstituted and does not fit the injectable peptide format.
Future Developments (2026-2028)
Amycretin (Novo): Oral GLP-1/Amylin agonist — Phase 2 shows -13% weight in 12 wk. Survodutide (Boehringer): GLP-1/Glucagon dual for MASH. Retatrutide (Lilly): Triple agonist — Phase 3, -24% weight (record). The trend: multiple agonists (dual/triple) + oral forms will dominate.
Related Guides
Frequently Asked Questions (FAQ)
Which GLP-1 drug gives the most weight loss?
Tirzepatide (Mounjaro/Zepbound) at 15mg/week achieved -22.5% body weight in SURMOUNT-1 — the highest in any obesity pharmacotherapy trial.
Can oral GLP-1s replace injectables?
Not yet in equivalent efficacy. Orforglipron (36mg oral) achieved ~9-10% vs ~15-22% for injectables. However, Amycretin (oral) looks very promising (-13% in 12 wk).
Why is Orforglipron important?
It's the first non-peptide oral GLP-1 — no SNAC or fasting requirements. This dramatically reduces production cost and increases adherence.
References & Studies
Disclaimer
This article is exclusively educational and based on published clinical trials (STEP, SURMOUNT, PIONEER, NEJM, Lancet). It does not constitute medical advice.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer